Literature DB >> 29858433

Crohn's disease: management in adults, children and young people - concise guidance .

Gloria Sz Tun1, Sarah Cripps2, Alan J Lobo3.   

Abstract

Crohn's disease (CD) is a chronic inflammatory condition of the gastrointestinal tract. Individuals with CD present with acute inflammatory exacerbations as well as acute and chronic complications. Management requires specialist input from gastroenterologists, colorectal surgeons, nurse specialists and pharmacists as well as general and primary care physicians to allow appropriate selection of treatment options including surgery and rapid assessment and treatment of those with acute exacerbations. Monitoring of the individual and their medication is crucial in preventing and recognising complications including those associated with treatment. This concise guideline focuses on recommendations from National Institute for Health and Care Excellence (NICE) -Clinical -Guideline 152 (CG152) considered of key importance for implementation. © Royal College of Physicians 2018. All rights reserved.

Entities:  

Keywords:  Crohn's disease; Treatment; inflammatory bowel disease

Mesh:

Substances:

Year:  2018        PMID: 29858433      PMCID: PMC6334085          DOI: 10.7861/clinmedicine.18-3-231

Source DB:  PubMed          Journal:  Clin Med (Lond)        ISSN: 1470-2118            Impact factor:   2.659


  16 in total

1.  Trough concentrations of infliximab guide dosing for patients with inflammatory bowel disease.

Authors:  Niels Vande Casteele; Marc Ferrante; Gert Van Assche; Vera Ballet; Griet Compernolle; Kristel Van Steen; Steven Simoens; Paul Rutgeerts; Ann Gils; Séverine Vermeire
Journal:  Gastroenterology       Date:  2015-02-24       Impact factor: 22.682

Review 2.  Infliximab reduces hospitalizations and surgery interventions in patients with inflammatory bowel disease: a systematic review and meta-analysis.

Authors:  João Costa; Fernando Magro; Daniel Caldeira; Joana Alarcão; Rita Sousa; António Vaz-Carneiro
Journal:  Inflamm Bowel Dis       Date:  2013-09       Impact factor: 5.325

Review 3.  Budesonide for induction of remission in Crohn's disease.

Authors:  Ali Rezaie; M Ellen Kuenzig; Eric I Benchimol; Anne Marie Griffiths; Anthony R Otley; A Hillary Steinhart; Gilaad G Kaplan; Cynthia H Seow
Journal:  Cochrane Database Syst Rev       Date:  2015-06-03

4.  Maintenance of remission among patients with Crohn's disease on antimetabolite therapy after infliximab therapy is stopped.

Authors:  Edouard Louis; Jean-Yves Mary; Gwenola Vernier-Massouille; Jean-Charles Grimaud; Yoram Bouhnik; David Laharie; Jean-Louis Dupas; Hélène Pillant; Laurence Picon; Michel Veyrac; Mathurin Flamant; Guillaume Savoye; Raymond Jian; Martine Devos; Raphaël Porcher; Gilles Paintaud; Eric Piver; Jean-Frédéric Colombel; Marc Lemann
Journal:  Gastroenterology       Date:  2011-09-22       Impact factor: 22.682

5.  Infliximab, azathioprine, or combination therapy for Crohn's disease.

Authors:  Jean Frédéric Colombel; William J Sandborn; Walter Reinisch; Gerassimos J Mantzaris; Asher Kornbluth; Daniel Rachmilewitz; Simon Lichtiger; Geert D'Haens; Robert H Diamond; Delma L Broussard; Kezhen L Tang; C Janneke van der Woude; Paul Rutgeerts
Journal:  N Engl J Med       Date:  2010-04-15       Impact factor: 91.245

Review 6.  Azathioprine or 6-mercaptopurine for induction of remission in Crohn's disease.

Authors:  Nilesh Chande; Cassandra M Townsend; Claire E Parker; John K MacDonald
Journal:  Cochrane Database Syst Rev       Date:  2016-10-26

7.  Development of a Crohn's disease activity index. National Cooperative Crohn's Disease Study.

Authors:  W R Best; J M Becktel; J W Singleton; F Kern
Journal:  Gastroenterology       Date:  1976-03       Impact factor: 22.682

8.  3rd European Evidence-based Consensus on the Diagnosis and Management of Crohn's Disease 2016: Part 1: Diagnosis and Medical Management.

Authors:  Fernando Gomollón; Axel Dignass; Vito Annese; Herbert Tilg; Gert Van Assche; James O Lindsay; Laurent Peyrin-Biroulet; Garret J Cullen; Marco Daperno; Torsten Kucharzik; Florian Rieder; Sven Almer; Alessandro Armuzzi; Marcus Harbord; Jost Langhorst; Miquel Sans; Yehuda Chowers; Gionata Fiorino; Pascal Juillerat; Gerassimos J Mantzaris; Fernando Rizzello; Stephan Vavricka; Paolo Gionchetti
Journal:  J Crohns Colitis       Date:  2016-09-22       Impact factor: 9.071

9.  Mercaptopurine versus placebo to prevent recurrence of Crohn's disease after surgical resection (TOPPIC): a multicentre, double-blind, randomised controlled trial.

Authors:  Craig Mowat; Ian Arnott; Aiden Cahill; Malcolm Smith; Tariq Ahmad; Sreedhar Subramanian; Simon Travis; John Morris; John Hamlin; Anjan Dhar; Chuka Nwokolo; Cathryn Edwards; Tom Creed; Stuart Bloom; Mohamed Yousif; Linzi Thomas; Simon Campbell; Stephen J Lewis; Shaji Sebastian; Sandip Sen; Simon Lal; Chris Hawkey; Charles Murray; Fraser Cummings; Jason Goh; James O Lindsay; Naila Arebi; Lindsay Potts; Aileen J McKinley; John M Thomson; John A Todd; Mhairi Collie; Malcolm G Dunlop; Ashley Mowat; Daniel R Gaya; Jack Winter; Graham D Naismith; Holly Ennis; Catriona Keerie; Steff Lewis; Robin J Prescott; Nicholas A Kennedy; Jack Satsangi
Journal:  Lancet Gastroenterol Hepatol       Date:  2016-08-30

10.  How are we managing fistulating perianal Crohn's disease? Results of a national survey of consultant gastroenterologists.

Authors:  Matthew James Lee; Steven R Brown; Nicola S Fearnhead; Ailsa Hart; Alan J Lobo
Journal:  Frontline Gastroenterol       Date:  2017-09-23
View more
  2 in total

1.  Correlation of Paraoxonase-1 with the Severity of Crohn's Disease.

Authors:  Katarzyna Szczeklik; Tomasz Mach; Dorota Cibor; Danuta Owczarek; Jacek Sapa; Monika Papież; Jolanta Pytko-Polończyk; Wirginia Krzyściak
Journal:  Molecules       Date:  2018-10-11       Impact factor: 4.411

2.  Gastrocolic fistula in Crohn's disease detected by oral agent contrast-enhanced ultrasound: A case report of a novel ultrasound modality.

Authors:  Shuang Wu; Hua Zhuang; Jie-Ying Zhao; Yu-Fang Wang
Journal:  World J Gastroenterol       Date:  2020-05-07       Impact factor: 5.742

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.